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Background. Cytoadherence and sequestration of erythrocytes containing mature stages of Plasmodium falcipa-
rum are central to the pathogenesis of severe malaria. The oral anthelminthic drug levamisole inhibits cytoadherence
in vitro and reduces sequestration of late-stage parasites in uncomplicated falciparummalaria treated with quinine.
Methods. Fifty-six adult patients with severe malaria and high parasitemia admitted to a referral hospital in Ban-
gladesh were randomized to receive a single dose of levamisole hydrochloride (150 mg) or no adjuvant to antimalarial
treatment with intravenous artesunate.
Results. Circulating late-stage parasites measured as the median area under the parasite clearance curves were
2150 (interquartile range [IQR], 0–28 025) parasites/µL × hour in patients treated with levamisole and 5489 (IQR,
192–25 848) parasites/µL × hour in controls (P = .25). The “sequestration ratios” at 6 and 12 hours for all parasite
stages and changes in microvascular blood ﬂow did not differ between treatment groups (all P > .40). The median time
to normalization of plasma lactate (<2 mmol/L) was 24 (IQR, 12–30) hours with levamisole vs 28 (IQR, 12–36) hours
without levamisole (P = .15).
Conclusions. There was no beneﬁt of a single-dose of levamisole hydrochloride as adjuvant to intravenous artesu-
nate in the treatment of adults with severe falciparum malaria. Rapid parasite killing by intravenous artesunate might
obscure the effects of levamisole.
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Severe malaria in adults has a high mortality rate between
15% and 30%, and no adjunctive treatment has been able
to reduce this unacceptably high ﬁgure [1]. Pivotal in the
pathogenesis of cerebral and severe Plasmodium falcipa-
rum malaria is sequestration of erythrocytes containing
mature stages of the parasite, which is augmented by en-
dothelial cell activation and dysfunction, culminating in
microvascular obstruction [2, 3]. A cheap and safe drug
targeting cytoadherence and thus sequestration in vital
organs would be a promising candidate for adjunctive
treatment in severe falciparum malaria.
Cytoadherence is mediated by the parasite protein
P. falciparum erythrocyte membrane protein 1 (PfEMP1)
[4], and endothelial receptor molecules, including CD36
[5, 6] intercellular adhesion molecule 1 (ICAM-1) [7],
E-selectin, and vascular cell adhesion molecule 1
(VCAM-1) [8]. Studies under physiological ﬂow condi-
tions have shown that the different adhesion molecules
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interact synergistically. The infected red blood cells tether and roll
on endothelial receptors with a low afﬁnity (ICAM-1, VCAM-1,
and P-selectin), facilitating the subsequent more-deﬁnite adhesion
to CD36 [9–12]. Peptide mapping studies have revealed that the
critical region on PfEMP1 involved in binding to CD36 is localized
to a 179–amino acid sequence within the cysteine-rich interdo-
main region 1 (CIDR-1). A recombinant 179–amino acid peptide
expressed in yeast (PpMC-179) represents this minimal CD36-
binding domain and is able to reduce cytoadherence of P. falcipa-
rum–infected red blood cells (IRBCs) by >80% in a human/severe
combined immunodeﬁciency (SCID) mouse chimeric model [13].
It was shown more recently that binding of PpMC-179 to CD36
on human dermal microvascular endothelial cells activates a physi-
cally closely associated Src-family kinase [14, 15]. This activation
results in an increased afﬁnity of CD36 for IRBCs through activa-
tion of an ecto-alkaline phosphatase (ecto-ALP), causing dephos-
phorylation of the extracellular domain of CD36 [16]. Selective
inhibition of the Src-family kinase by the pyrazolopyrimidine PP1
inhibits adhesion of IRBC by >70% in a ﬂow-chamber assay and
in a human/SCIDmouse chimeric model.
Levamisole hydrochloride is an old and cheap drug, primari-
ly used to treat intestinal helminths. It is a speciﬁc alkaline-
phosphatase inhibitor, and by targeting of the endothelial
ecto-ALP it decreases the adhesion of IRBCs to CD36. We per-
formed a small randomized controlled trial in 21 patients with
uncomplicated falciparum malaria on the antiadhesive effect of
a single oral dose of 150 mg of levamisole as adjunctive treat-
ment to quinine. It was shown that in patients treated with
levamisole, signiﬁcantly more late-stage parasites could be de-
tected in the peripheral blood over time, which was attributed
to the inhibition of sequestration with levamisole [17]. No
adverse effects of levamisole were observed in this study. Vom-
iting is a common side effect of levamisole when used in repeat-
ed high doses as an adjunctive therapy with 5-ﬂuorouracil in
colon cancer chemotherapy, but is uncommon in low doses as
used in antihelminth treatment and this study [18].
Because of these encouraging results, we performed an open-
label randomized controlled trial of levamisole hydrochloride
as adjuvant treatment in adult patients with severe falciparum
malaria to study its effect on sequestration of infected red blood
cells. At the time of the study, artesunate had replaced quinine
as ﬁrst-line treatment for severe malaria, so levamisole was
studied as an adjunct to artesunate rather than quinine [19].
METHODS
Study Site and Patients
The study was conducted at Chittagong Medical College Hos-
pital, Chittagong, Bangladesh, from May 2006 to August 2010.
Chittagong Medical College Hospital is a 1000-bed teaching
hospital with limited facilities for oxygen therapy, blood trans-
fusion, intensive care, and renal dialysis. Malaria transmission
is seasonal and of low intensity in this location. Ethical clear-
ance was obtained from the Ministry of Health in Bangladesh,
and from the Oxford Tropical Research Ethics Committee (reg-
istration number: ISRCTN 27232551).
Adult patients (aged ≥16 years) with slide-conﬁrmed severe
P. falciparum malaria (according to modiﬁed World Health
Organization [WHO] criteria [20]) and parasitemia of >2%
were recruited, provided that written informed consent was
obtained from the patient or an attending relative.
Criteria for severe malaria included coma (Glasgow Coma
Score [GCS] <11), pulmonary edema, repeated convulsions (≥2
in 24 hours), severe anemia (hematocrit level <20%, plus a par-
asite count >100 000 parasites/µL) or jaundice (bilirubin level
>3.0 mg/dL, plus a parasite count >100 000 parasites/µL), renal
failure (serum creatinine level >3 mg/dL), hypoglycemia (blood
glucose level <40 mg/dL), shock (systolic blood pressure < 80
mm Hg with cool extremities), hyperparasitemia (peripheral
asexual stage parasitemia >10%), hyperlactemia (venous plasma
lactate >4 mmol/L), and/or acidemia (venous plasma bicarbon-
ate level <15 mmol/L) [20].
Exclusion criteria were known allergies to levamisole or
artesunate, >1 dose of another antimalarial treatment within
1 week before admission, pregnancy, and breastfeeding.
Drug Treatment
Patients were randomly assigned to either adjunctive treatment
with levamisole, or no adjunctive treatment, in addition to par-
enteral artesunate. Computerized randomization was balanced
in blocks of 20, and allocation codes were kept in sealed enve-
lopes. Patients, nurses, and laboratory scientists were masked to
the treatment assigned. Levamisole treatment was directly
observed by a study physician.
Levamisole was obtained as 25-mg tablets (Actavis Ltd, for-
merly Pharmamed Ltd) and was given simultaneously with the
ﬁrst dose of intravenous artesunate as a single dose of 150 mg
(6 tablets of 25 mg) dissolved in sterile water. This dose is the
same as that used in the treatment of Ascaris lumbricoides in-
fections [18]. For all unconscious patients unable to swallow
medication, a nasogastric tube was inserted. The dissolved le-
vamisole was administered by this route. Those not allocated to
receive levamisole were given only water. The solubility of le-
vamisole is excellent (210 g/L). The recovery of levamisole hy-
drochloride aqueous solution from tablets has been reported to
be 100% ± 2.1%, with good stability [21].
All patients were treated with parenteral artesunate (Guilin
No. 2 Pharmaceutical Factory) according to the WHO treat-
ment guidelines [19]. Supportive treatments were in accordance
with WHO [19] and local hospital guidelines.
Study Procedures
On admission, a full medical history and examination were carried
out. Venous blood samples were obtained for hemoglobin,
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hematocrit, parasitemia, platelet count, white cell count, plasma
lactate levels, glucose levels, and full biochemistry. Peripheral
blood parasitemia and staging in thin ﬁlms were assessed on
admission from 2 separate blood samples, and then at 1, 2, 3, 4, 5,
6, 8, 10, and 12 hours after admission, followed by every 4 hours
until parasite clearance, deﬁned as 2 consecutive negative blood
ﬁlms.
Assessment of Parasite Sequestration Dynamics
Primary outcome measures were dynamics of peripheral blood
parasitemia and stage distribution [17]. These were assessed by
measuring the area under the curve to 30 hours of the late stage–
speciﬁc (late trophozoites and schizonts) parasite clearance curves
comparing levamisole-treated patients with the control group.
In addition, the ratios between the observed and expected
peripheral blood parasite densities of deﬁned parasite develop-
mental stages determined on the basis of validated morphologi-
cal assessment were calculated at 6 and 12 hours after
admission as sequestration ratios (SQRs) [17]. The SQR for a
developmental stage of the parasite at a certain sample time
point after admission was deﬁned as follows:
SQR ¼ Parasitesobserved
ParasitesexpectedCf ;
Where:
Parasitesobserved is the observed number of parasites at the
sample time, that is, the peripheral blood parasitemia per
microliter of the developmental stage under consideration,
assessed from a peripheral blood slide.
Parasitesexpected is the expected number of parasites at the
same sample time, that is, the number of parasites per microliter
of that developmental stage expected to be present in the
peripheral blood if the matching cohort of circulating young-
form parasites on admission had developed unrestricted to the
later developmental stage under consideration, without seques-
tration in the microvasculature, and without (splenic) clearance.
Cf is the fraction of parasites cleared by the spleen and through
antimalarial drug action. This constant cannot be assessed in
vivo, but was assumed to be the same in both treatment arms.
The area under the parasitemia-time curve over the ﬁrst 30
hours for mature forms of the parasite (late trophozoites and
schizonts) and the percentages of parasites that were trophozo-
ites over the ﬁrst 12 hours were also compared between the le-
vamisole and control groups.
Lactate
Plasma lactate was measured on admission, and then every 4
hours until parasite clearance, and then daily until full recovery
of the patient. Lactate clearance time was the time to a decrease
in plasma concentrations to <2 mmol/L (upper limit of normal
value).
Parasite Clearance
Parasite clearance rates and clearance slope half-lives were de-
termined using the WorldWide Antimalarial Resistance
Network Parasite Clearance Estimator [22]. Parasite clearance
time was deﬁned as the interval between start of treatment and
the ﬁrst of 2 sequential negative thick peripheral blood ﬁlms.
Parasite reduction ratios at 6 hours (PRR6), 12 hours (PRR12),
24 hours (PRR24), and 48 hours (PRR48) were deﬁned as the
ratio of the parasite count at admission to that at 6, 12, 24, or
48 hours [23].
Plasmodium falciparum Histidine-Rich Protein 2
Plasma P. falciparum histidine-rich protein 2 (PfHRP2) was as-
sessed by enzyme-linked immunosorbent assay (Cellabs) from
an EDTA plasma sample on admission. This provides an esti-
mate of the total body parasite burden [24]. The total peripher-
al blood parasite burden was calculated from peripheral blood
ﬁlm parasite counts. The ratio of total to circulating parasite
biomass as an indicator of the degree of sequestration was cal-
culated by dividing these 2 parameters.
Microvascular Flow
Microvascular blood ﬂow was measured in capillaries in the
rectal mucosa by orthogonal polarizing spectroscopy (OPS)
[25] at 0, 6, and 24 hours. At each time point, 3 videos of
minimum 10 seconds’ duration were recorded. These were then
anonymized and scored by 2 independent blinded observers. In
each video, 20 capillaries were scored as “ﬂow,” “no ﬂow,” or
“uncertain,” and the proportion of capillaries with ﬂow in the 3
videos per time point was calculated. The change in proportion
of capillaries with ﬂow over time was then used as the outcome
measure.
Levamisole Pharmacokinetics
A venous blood sample at 0, 4, 6, and 12 hours after levamisole
administration was taken for pharmacokinetic assessment.
Levamisole concentrations were determined using a high-
performance liquid chromatography method adapted from
Vandamme et al [26].
Plasma levamisole pharmacokinetics were characterized with
nonlinear mixed-effects modeling using NONMEM version 6
(Icon Development Solutions). A ﬁrst-order conditional esti-
mation method allowing an interaction term was used for mod-
eling, and basic diagnostics were visualized using Xpose 4.0
[27]. A one-compartment model with ﬁrst-order absorption
kinetics allowing a lag time has previously been described for
levamisole in cancer patients [28]. This structural model was
maintained as only sparse data were available from this study.
An absorption lag time, however, was not used in this analysis
as only one data point was collected during the absorption
phase. EmpiricalBayes estimates fromthepopulationmodelwere
used for individual predictions of maximum concentration and
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area under the plasma concentration-time curve (AUC). These
pharmacokinetic parameters were correlated with the seques-
tration ratio as the primary pharmacodynamic measure of in-
terest.
Other Assessments
Fever was assessed at all sample times, as this can affect the cy-
toadherent properties of IRBCs [29]. Vital signs, oxygen satura-
tion, level of consciousness (GCS), ﬂuid input, and output were
recorded every 6 hours until recovery. Patients were followed
until discharge from the hospital.
Statistical Procedures
Statistical analysis was performed using SPSS (version 15.0)
and Stata software (version 10). Data were log-transformed to
obtain a normal distribution, where appropriate. Normally dis-
tributed data were compared using Student t test, and the
Mann–Whitney U test was used for nonpaired nonparametric
data. Categorical data were compared by Pearson χ2 test and
Fisher exact test, as appropriate. The Spearman rank test was
used to assess correlations between nonnormally distributed
data. Kaplan–Meier plots were constructed for time-dependent
parameters. For comparison between treatment groups (Wil-
coxon–Breslow test), the lactate clearance times in patients who
died before clearance or recovery were set as maximum time
(rather than censored), as persistent high plasma lactate con-
centrations are strongly associated with a fatal course of the
disease [30]. The level of signiﬁcance was set at P < .05.
The power calculation for this study was based on a previous
in vivo study of uncomplicated falciparum malaria patients re-
ceiving levamisole plus quinine vs quinine alone [17]. A
sample size of 60 patients was calculated, based on an expected
standardized difference of 1 in the area under the time-parasi-
temia curve, a power of 85%, and a signiﬁcance level of 5%.
RESULTS
Fifty-six patients with severe malaria were enrolled and ran-
domized to receive either levamisole as an adjunctive treatment
to artesunate (n = 29) or artesunate alone (n = 27). A
CONSORT diagram of the trial is shown in Figure 1.
Baseline Characteristics
The baseline characteristics are summarized in Tables 1 and 2,
and did not differ between treatment groups except for jaun-
dice, which was slightly higher in the group not receiving
levamisole. The plasma levels of PfHRP2 and calculated total
biomass are shown in Table 1. At baseline, there was no
difference between the median ratio of sequestered to nonse-
questered parasite biomass in those receiving levamisole
(10.5 [95% conﬁdence interval {CI}, 4.1–21.6]) and those not
receiving levamisole (13.1 [95% CI, 8.8–35.6], P = .176).
Five patients (17%) in the levamisole-treated group died,
compared to 9 patients (33%) in the control group (P = .221).
Median time to death was 1.21 (interquartile range [IQR],
0.97–1.5) hours for the levamisole group and 1.00 (IQR, 0.87–
1.65) hours in the nonlevamisole group (P = .928). Of patients
who died, 11 of 14 (79%) had cerebral malaria, 6 of 14 (43%)
had severe acidosis, 1 of 14 (7%) had renal failure, and 3 of 14
(21%) developed acute respiratory distress syndrome. Postmor-
tems were not possible in our study setting.
Dynamics of Peripheral Blood Parasitemia and Stage
Distribution
The median integrated number of late-stage parasites (late tro-
phozoites and schizonts) in the peripheral blood slides during
the ﬁrst 30 hours after admission was 2150 (IQR, 0–28 025)
parasites/µL × hour in the levamisole group compared to 5489
(IQR, 192–25 848) parasites/µL × hour in the control group
(P = .25). The median integrated number of total trophozoites
in peripheral blood slides during the ﬁrst 30 hours after admis-
sion was 265 517 (IQR, 69 177–551 432) parasites/µL × hour in
the levamisole group and 352 053 (IQR, 144 556–666 539)
parasites/µL × hour in the control group (P = .515). The pro-
portions of trophozoites in the peripheral blood slide over time
are shown in Figure 2. There was no difference between treat-
ment groups in the change over time in these proportions.
Table 3 shows the sequestration ratios compared between
treatment groups. A higher sequestration ratio indicates pre-
vention of sequestration if clearance (Cf) is assumed to be
similar in both groups. After 6 hours, the mean sequestration
ratio for early trophozoites was >1 in both study arms, implying
absence of signiﬁcant sequestration or splenic clearance of early
trophozoites at this time point. For all other stages at 6 and 12
hours, the sequestration ratio was <1, implying a high degree of
sequestration or splenic clearance of the more mature parasite
stages. There was no difference in the extent of sequestration
measured as sequestration ratio between the 2 treatment arms.
The parasite clearance rates, clearance slope half-lives,
parasite clearance times, PRR6, PRR12, PRR24, and PRR48 are
shown in Table 4. The PRR6, PRR12, PRR24, and PRR48 were
greater in the levamisole group, but there was no difference in
the other measures of parasite clearance. There was no diffe-
rence in parasite clearance half-lives between fatal and nonfatal
infections (median, 3.23 [IQR, 1.49–3.42] hours and 2.37 [IQR,
2.03–3.12] hours, respectively, P = .910).
Microvascular Flow
OPS was performed both on enrollment and at 6 and/or 24
hours in 12 patients in the levamisole group and 9 patients in
the nonlevamisole group. Those who died before 6 or 24 hours
could not have follow-up OPS, and OPS was not possible in
those patients with signiﬁcant diarrhea or who did not tolerate
the procedure. There was no difference in improvement of
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microcirculatory ﬂow assessed as the change in proportion of
capillaries with ﬂow: from 0 to 6 hours the median change was
6.7% (IQR, −10.5% to 26.8%) with levamisole vs 3.8% (−4.0%
to 25.0%) without levamisole (P = .96); from 6 to 24 hours the
median change was −0.7% (IQR, −5.0% to 14.2%) with levami-
sole vs 8.7% (IQR, −2.5% to 23.6%) without levamisole
(P = .41); from 0 to 24 hours the median change was 16.8%
(IQR, −0.75% to 26.7%) with levamisole vs 20.8% (−8.3% to
24.8%) without levamisole (P = .96). The median proportions
of capillaries with ﬂow in patients treated with levamisole were
77% (IQR, 68.5%–94%) at enrollment, vs 86.5% (IQR, 74.8%–
99.0%) after 6 hours, and 91.5% (IQR, 86.8%–97.0%) after 24
hours; in patients not treated with levamisole, the median pro-
portion was 78% (IQR, 64.8%–92.8%) at enrollment, 90.0%
(IQR, 73.5%–95.0%) after 6 hours, and 91.5% (IQR, 68.8%–
95.0%) after 24 hours, respectively.
Lactate Clearance
Elevated admission plasma lactate concentrations (>2 mmol/L)
were present in 48 of 56 patients (86%), 25 (86%) in the levami-
sole group and 23 (85%) in the nonlevamisole group. Baseline
PfHRP2 correlated with plasma lactate (Spearman r = 0.44,
P = .001). Hyperlactemia (>4 mmol/L) was present in 13 of 29
(45%) and 15 of 27 (56%) patients, respectively. Median lactate
clearance time was 24 hours (IQR, 12–30 hours) in the levami-
sole-treated and 28 (IQR, 12–36 hours) in the control group
(P = .148, excluding patients who died). The Kaplan–Meier
survival analysis for lactate clearance time (Figure 3) showed no
Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram of the trial.
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Table 1. Baseline Characteristics
Variable Levamisole (n = 29) Control (n = 27) P Valuea
Age, yb 30 (25–45) 28 (21–45) .774
Male/female sex, No. 18/11 22/5 .242
Temperature, °C 37.8 (37.4–38.3) 38.0 (37.5–38.6) .589
Systolic blood pressure, mm Hg 104 (97–111) 105 (97–113) .883
Oxygen saturation, % 95 (94–96) 95 (94–96) .79
Glasgow Coma Scoreb 10 (8–15) 10 (6–13.5) .167
Hematocrit, % 27.0 (23.3–30.7) 28.5 (25.2–31.7) .942
Peripheral white blood cell count, cells/µL 10 559 (8510–12 608) 8504 (6946–10 062) .329
Platelet count, cells/µL 94 630 (68 445–120 814) 72 960 (44 626–101 294) .79
Parasitemia, parasites/µLc 294 775 (227 483–381 973) 236 742 (171 156–327 461) .333
Trophozoites and schizonts, %b 3 (1–18) 3 (1–19) .965
Plasma HRP2, µg/L 5802 (3336–8268) 6887 (3998–9777) .578
Plasma HRP2-derived parasite burden, per patientc 1.09 × 1013 (5.95 × 1012–2.01 × 1013) 1.68 × 1013 (8.82 × 1012–3.25 × 1013) .324
Ratio total/circulating parasite biomass 10.5 (4.1–21.6) 13.1 (8.8–35.6) .176
Sequestered proportion of parasite biomass, % 85 (79–91) 90 (85–96) .212
Serum creatinine, mg/dLc 1.5 (1.2–1.9) 1.6 (1.3–1.9) .527
Total serum bilirubin, mg/dLc 3.3 (2.5–4.4) 4.2 (2.7–6.8) .329
Serum albumin, g/100 mL 2.9 (2.6–3.2) 2.5 (2.3–2.8) .083
Serum aspartate aminotransferase, U/Lc 86 (67–110) 108 (82–141) .412
Serum alanine aminotransferase, U/Lc 24 (20–31) 33 (26–43) .079
Plasma lactate, mmol/Lc 4.6 (3.6–5.9) 5.4 (4.4–6.6) .1
Venous bicarbonate, mmol/L 18.9 (16.9–20.9) 16.5 (14.7–18.3) .126
Plasma base excess, mmol/L −5.1 (−7.8 to −2.5) −8.2 (−10.4 to −6.0) .11
Data are presented as mean (95% confidence interval) unless otherwise indicated.
a Student t test for normal distributed data and Mann–Whitney U test for the remainder.
b Median (interquartile range).
c Geometric mean (95% confidence interval).
Table 2. Markers of Severe Malaria Present on Admission
Marker
Levamisole
(n = 29), No. (%)
Control (n = 27),
No. (%) P Valuea
Glascow Coma Score <11 15 (52) 17 (63) .396
Hematocrit <20%with parasite count >100 000 parasites/µL 4 (14) 3 (11) 1
Bilirubin >30 with parasite count >100 000 parasites/µL 0 (0) 4 (15) .048
Serum creatinine >3 mg/dL 4 (14) 2 (7) .671
Glucose <40 mg/dL 1 (3) 1 (4) 1
Shock (SBP <80 mmHg plus cool peripheries) 2 (7) 1 (4) 1
Parasitemia >10% 15 (52) 10 (37) .269
Venous lactate >4 mmol/L 13 (45) 15 (56) .422
Venous bicarbonate <15 mmol/L 7 (24) 10 (37) .251
Pulmonary edema 0 (0) 3 (11) .106
Spontaneous bleeding 2 (7) 3 (11) .664
Generalized convulsions (≥2 per 24 h) 7 (24) 4 (15) .506
Abbreviation: SBP, systolic blood pressure.
a χ2 test.
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difference between treatment groups (Wilcoxon–Breslow test,
P = .3).
Levamisole Pharmacokinetics
The mean maximum plasma concentration (Cmax) of levamisole
for levamisole-treated patients was 703 (95% CI, 535–871) ng/mL,
and the mean AUC was 10.7 (95% CI, 9.0–12.4) mg/L/hour. This
is similar to values reported in previous studies [31]. There was no
correlation between the sequestration ratio (at 6 and 12 hours)
and levamisole Cmax or AUC, except for the sequestration of early
trophozoites at 6 hours (AUC P = .05, Cmax P = .005) and small
rings at 12 hours (AUC P = .03, Cmax P = .6).
DISCUSSION
In this study we were unable to detect a beneﬁcial effect of
levamisole as adjuvant therapy to intravenous artesunate in the
treatment of adult severe malaria.
Our earlier study showed that sequestration was reduced by
levamisole in patients with uncomplicated malaria treated with
quinine, as indicated by an initial increase in peripheral late-
stage parasitemia on peripheral blood smear, which was quanti-
ﬁed by comparing sequestration ratios [17]. The present study
shows that there is no signiﬁcant change in sequestration in pa-
tients with severe malaria treated with levamisole as an adju-
vant to intravenous artesunate.
The main difference with our earlier study is that in the
current study, artesunate rather than quinine was used as antima-
larial treatment. Quinine has a slow onset of action, and only kills
trophozoite- and schizont-stage parasites [32]. In contrast, artesu-
nate has a rapid onset of action within 4 hours after administra-
tion and a broad-stage speciﬁcity, also killing ring-stage parasites
[32]. The pharmacodynamic properties of artesunate result in fast
splenic clearance of ring-stage parasites, preventing their further
maturation and sequestration in the microcirculation. Indeed, the
appearance of late-stage parasites in the peripheral blood at 6
hours after admission or later was virtually absent in the current
study, but prominent in uncomplicated malaria patients treated
with quinine [17]. The calculated sequestration ratio, used to
quantify sequestration, cannot distinguish between microcircula-
tory sequestration and splenic clearance. Splenic clearance is a
minor confounder in the initial hours after slow-acting quinine,
but a major confounder after rapidly acting artesunate [32]. The
observed low sequestration ratios after start of treatment in the
current study can thus express either high splenic clearance or
microvascular sequestration. The greater parasite reduction ratio
in patients treated with levamisole could be explained by a reduc-
tion in initial parasite sequestration, so that the parasites are
exposed to splenic clearance. However, the parasite clearance rate
after the initial lag time in clearance (shorter with levamisole)
was the same in both treatment groups.
It is likely that the lack of effect of levamisole in the current
study is the high parasiticidal potency of artesunate resulting in
fast ring-stage and later-stage parasite clearance. Because this
Table 3. Sequestration Ratios
Time, Stage Levamisole (n = 29) Control (n = 27) P Valuea
SQR×Cf at 6 hours
Early trophozoites (ET/LR) 1.28 (.57–2.91) 1.07 (.40–2.85) .79
Late rings (LR/SR) 0.05 (.02–.13) 0.06 (.03–.12) .70
Mid-trophozoites (MT/ET) 0.16 (.05–.54) 0.27 (.09–.85) .54
SQR×Cf at 12 hours
Early trophozoites (ET/SR) 0.05 (.02–.16) 0.10 (.04–.26) .41
Small rings (SR/TR) 0.13 (.05–.36) 0.14 (.06–.35) .91
Mid-trophozoites (MT/LR) 0.06 (.02–.23) 0.03 (.00–.16) .47
Data are presented as geometric mean (95% confidence interval).
Abbreviations: Cf, fraction cleared by the spleen, assumed the same for both treatment arms; ET, early trophozoites; LR, late rings; MT, mid-trophozoites; SQR,
sequestration ratio; SR, small rings.
a Student t test.
Figure 2. Percentage of trophozoites over time. Boxes represent
median (quartiles) and whiskers represent range.
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fast clearance by artesunate might have obscured the effect of
levamisole, a beneﬁcial effect as adjunctive treatment in severe
malaria cannot be entirely excluded.
In addition, mechanisms of sequestration are thought to differ
within the human host at different anatomical sites. In the pe-
ripheral endothelium, CD36 is primarily expressed, whereas in
the brain ICAM and VCAM are more prominent. It is possible
that in this study population of patients with severe malaria,
endothelial receptors other than CD36 play a larger role mediat-
ing sequestration in the systemic circulation, thus reducing the
potential effect of levamisole, which speciﬁcally inhibits cytoad-
herence to CD36.
Plasma lactate concentrations are a crude marker of tissue
oxygenation and microcirculatory ﬂow, and have a strong pre-
dictive value for mortality in severe malaria [30, 33]. In the
current study, we could not show a difference between treat-
ment groups in lactate clearance times or the Kaplan–Meier
lactate survival curves. Again, a potential effect of levamisole
might have been obscured by the potent action of artesunate.
Despite the presence of severe illness, absorption of levami-
sole was reliable with a mean plasma level of 96.5% ± 1.5 of that
expected in healthy adults. In a previous study, the peak levels
of levamisole in the plasma were reached after 1–2 hours [34].
The lack of a pharmacodynamic effect on sequestration can
thus not be explained by inadequate absorption of levamisole
after oral administration.
A variety of other adjunctive treatments aimed at reducing
mortality from severe malaria have been evaluated in clinical
trials without showing evidence of beneﬁt, including adrenaline
[35], anti–tumor necrosis factor antibody [36], aspirin [37], dexa-
methasone [38], heparin [37], human albumin [39], intravenous
immunoglobulin [40], iron chelators [41, 42], low-molecular-
weight dextran [43], mannitol [44, 45], N-acetylcysteine [46],
phenobarbitone [47], and ursodeoxycholic acid [48].
In conclusion, we could not show a beneﬁcial effect of
levamisole as adjunctive therapy to artesunate in adult patients
with severe falciparum malaria. It is possible that the potent
and rapid onset of the parasiticidal effect of artesunate obscures
the inhibiting effects on sequestration of levamisole.
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